Factors Affecting Bleeding in Patients with Atrial Fibrillation Receiving Rivaroxaban : A Multicenter Matched Case-Control Study
Article Sidebar
Main Article Content
Abstract
Objective: To investigate factors affecting bleeding in patients with atrial fibrillation receiving rivaroxaban. Methods: This research was a multicenter, matched case-control study. Data were collected from patients with atrial fibrillation receiving rivaroxaban at King Chulalongkorn Memorial Hospital and Ramathibodi Hospital from October 1, 2013 to September 30, 2021. Case-control pairs were matched (1:1) with gender and age. The factors affecting bleeding were analyzed using multiple logistic regression. Results: A total of 182 patients were divided into two groups. Ninety-one case-patients with bleeding consisted of 20 patients with major bleeding, 45 patients with clinically relevant non-major bleeding and 26 patients with minor bleeding. The control group was 91 patients without bleeding. Factors significantly affecting bleeding included history of bleeding (adjusted OR: 11.23, 95%CI= 3.94, 31.97; P < 0.001) and hypoalbuminemia (adjusted OR: 2.22, 95%CI=1.01, 4.89; P = 0.047) after adjusted with rivaroxaban daily dose, creatinine clearance, inappropriate dose with too high dose, anemia, and drug interactions. Conclusion: Factors affecting bleeding in patients with atrial fibrillation receiving rivaroxaban were history of bleeding and hypoalbuminemia. Therefore, patients with these factors should be monitored to reduce risk of bleeding and improve safety of rivaroxaban use.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Phrommintikul A, Detnuntarat P, Prasertwitayakij N, Wongcharoen W. Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol 2016; 13: 270-3.
Lippi G, Sanchisgomar F, Cervellin G. Global epide miology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke 2021; 16: 217-21.
Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016; 176: 1662-71.
Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Saxena A, et al. 2017 consensus of the Asia Pacific heart rhythm society on stroke prevention in atrial fibrillation. J Arrhythm. 2017; 33: 345-67.
Kiatchoosakun S, Pachirat O, Chirawatkul A, Chopra pawan C, Tatsanavivat P. Prevalence of cardiac arrhy thmias in Thai community. J Med Assoc Thai. 1999; 82: 727-33.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Boriani G, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation deve- loped in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020; 42: 373-498.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Ellinor PT, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019; 74: 104-32.
Schulman S. New oral anticoagulant agents - general features and outcomes in subsets of patients. Thromb Haemost. 2014; 111: 575-82.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383: 955-62.
Rivaroxaban. In: DRUGDEX [database on the Internet]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 Jul 24]. Available from: www.micro medexsolutions.com.
Mitsuntisuk P, Nathisuwan S, Junpanichjaroen A, Wongcharoen W, Phrommintikul A, Wattanarueng chai P, et al. Real-world comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants vs warfarin in a developing country. Clin Pharmacol Ther. 2021; 109: 1282-92.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021; 23: 1612-76.
Akhtar T, Fratti JDC, Mattumpuram J, Fugar S, Uprety A, Nwaichi C, et al. Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience. Int J Cardiol. 2020; 320: 78-82.
Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, Turpie AGG, et al. Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with rivaroxaban. J Am Heart Assoc. 2020; 9: 1-11.
Miyamoto S, Ikeda T, Ogawa S, Kitazono T, Nakaga wara J, Minematsu K, et al. Clinical risk factors of thromboembolic and major bleeding events for patients with atrial fibrillation treated with rivaroxaban in Japan. J Stroke Cerebrovasc Dis. 2020; 29: 1-9.
Sakaguchi T, Osanai H, Murase Y, Ishii H, Nakashi- ma Y, Asano H, et al. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017; 70: 244-9.
Sakuma I, Uchiyama S, Atarashi H, Inoue H, Kitazo- no T, Yamashita T, et al. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND study sub-analysis. Heart Vessels. 2019; 34: 1839-51.
Sosothikul D. Self-care for prone to bleeding: the Thai society of hematology [online]. 2021 [cited Jul 24, 2022]. Available from: tsh.or.th/Knowledge/Details /73.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3: 692-4.
Parker RA, Bregman DJ. Sample size for indivi- dually matched case-control studies. Biometrics. 1986 ; 42: 919-26.
Peduzzi P, Concato J, Kemper E, Holford TR, Fein- stein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996; 49: 1373-9.
Hosmer DW, Lemeshow S. Applied logistic regres- sion. 3rd ed. Hoboken: John Wiley & Sons; 2013. p. 89-91.
World Health Organization. Haemoglobin concen- trations for the diagnosis of anaemia and assessment of severity [online]. 2011 [cited Jul 24, 2022]. Available from: apps.who.int/iris/bitstream/handle/106 65/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22&isAllowed=y.
Wojakowski E, Cheruvil C, Hassan A, Holsen MR, Chen L, Rossi M, et al. Albumin and bleed risk in riva roxaban treated patients. J Thromb Thrombolysis. 2020; 50: 1004-11.
Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, López-López A, Redondo-Diéguez A, Álvarez-Iglesias D, et al. Comparative evaluation of HAS-BLED and ATRIA scores by investigating the full potential of their bleeding prediction schemes in non-valvular atrial fibrillation patients on vitamin-K antagonists. Int J Cardiol. 2014; 176: 1259-61.
Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010; 71: 1565-75.
Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. Clin Cardiol. 2015; 38: 555-61.
Fang MC, Go AS, Chang Y, Borowsky LH, Pome rnacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011; 58: 395-401.
O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015; 36: 3258-64.
Rutherford O-CW, Jonasson C, Ghanima W, Holst R, Halvorsen S. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart. 2018; 5: 1-8.
